TopiVert Begins Phase 1 Study of Oral TOP1288 as Colitis Treatment

TopiVert Begins Phase 1 Study of Oral TOP1288 as Colitis Treatment
The first participant has been dosed in a Phase 1 American study evaluating TopiVert Pharma‘s oral version of TOP1288 as a treatment for ulcerative colitis (UC). The study will assess TOP1288’s safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers. Pharmacokinetics refers to the body’s absorption, distribution, metabolism, and excretion of a substance. Pharmacodynamics refers to its biological

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *